Literature DB >> 21422398

Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked.

Dimitrios Farmakis1, Athanasios Aessopos.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21422398     DOI： 10.1161/CIRCULATIONAHA.110.988089

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  24 in total

Review 1.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

2.  Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Authors:  Claudia R Morris; Hae-Young Kim; Elizabeth S Klings; John Wood; John B Porter; Felicia Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Kathryn Hassell; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Sandra Larkin; Jung H Suh; Elliott P Vichinsky; Frans A Kuypers
Journal:  Br J Haematol       Date:  2015-04-24       Impact factor: 6.998

Review 3.  The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.

Authors:  Jeffrey C Robinson; Brian B Graham; Tracey C Rouault; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2014-12       Impact factor: 6.914

4.  Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature.

Authors:  Kamonpun Ussavarungsi; Charles D Burger
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

5.  Response to "efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18.

Authors:  Elizabeth S Klings; Elliott P Vichinsky; Claudia R Morris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

6.  Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up.

Authors:  Giorgio Derchi; Manuela Balocco; Patrizio Bina; Vincenzo Caruso; Domenico G D'Ascola; Roberto Littera; Raffaella Origa; Maria D Cappellini; Gian L Forni
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

Review 7.  Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.

Authors:  Junaid Ansari; Youmna E Moufarrej; Rafal Pawlinski; Felicity N E Gavins
Journal:  Expert Rev Hematol       Date:  2017-12-05       Impact factor: 2.929

8.  Pulmonary hypertension in well-transfused thalassemia major patients.

Authors:  Antonella Meloni; Jon Detterich; Alessia Pepe; Paul Harmatz; Tom D Coates; John C Wood
Journal:  Blood Cells Mol Dis       Date:  2014-11-24       Impact factor: 3.039

9.  Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Authors:  Claudia R Morris; Hae-Young Kim; John Wood; John B Porter; Elizabeth S Klings; Felicia L Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Sylvia T Singer; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Vandana Sachdev; Sandra Larkin; Jung H Suh; Frans A Kuypers; Elliott P Vichinsky
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

10.  Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.

Authors:  Sylvia T Singer; Frans Kuypers; Jeffery Fineman; Ginny Gildengorin; Sandra Larkin; Nancy Sweeters; Howard Rosenfeld; Gregory Kurio; Annie Higa; Michael Jeng; James Huang; Elliott P Vichinsky
Journal:  Ann Hematol       Date:  2014-02-28       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.